Skip Navigation



JAC Advance Access published online on August 31, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki288
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/4/745    most recent
dki288v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pitisuttithum, P.
Right arrow Articles by Hardalo, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pitisuttithum, P.
Right arrow Articles by Hardalo, C. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org
Received April 8, 2005
Revised July 14, 2005
Accepted July 24, 2005

Original article

Activity of posaconazole in the treatment of central nervous system fungal infections

Punnee Pitisuttithum 1*, Ricardo Negroni 2, John R. Graybill 3, Beatriz Bustamante 4, Peter Pappas 5, Stanley Chapman 6, Roberta S. Hare 7, and Catherine J. Hardalo 7

1 Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok 10400, Thailand
2 Hospital FJ Muñiz, Buenos Aires, Argentina
3 University of Texas Health Sciences Center, San Antonio, TX, USA
4 Hospital Nacional Cayetano Heredia, Lima, Peru
5 University of Alabama at Birmingham, Birmingham, AL
6 University of Mississippi Medical Center Division of Infectious Diseases, Jackson, MS
7 Schering-Plough Research Institute, Kenilworth, NJ, USA

* To whom correspondence should be addressed.
Punnee Pitisuttithum, E-mail: tmppt{at}mahidol.ac.th; punneep@dmc.inet.co.th


  Abstract

Objectives: A multinational, multicentre, open-label clinical trial was conducted to evaluate the safety and efficacy of posaconazole, an extended-spectrum triazole antifungal agent, in subjects with invasive fungal infections who had refractory disease or who were intolerant of standard antifungal therapy. In this subanalysis, we report on those subjects in this trial who had a fungal infection that involved the CNS.

Methods: Subjects received posaconazole oral suspension 800 mg/day in divided doses for up to 1 year; however, subjects could receive additional therapy as part of a treatment-use extension protocol. A blinded, third-party data review committee determined subject eligibility and outcome.

Results: Of the 330 subjects who enrolled in the study, 53 had infections of the CNS, of which 39 were considered evaluable for efficacy. Most had refractory disease (37 of 39) and underlying HIV infection (29 of 39). Twenty-nine subjects had cryptococcal infections, and 10 had infections caused by other fungal pathogens [Aspergillus spp. (four), Pseudallescheria boydii (two), Coccidioides immitis (one), Histoplasma capsulatum (one), Ramichloridium mackenziei (one), and Apophysomyces elegans plus a Basidiomycetes sp. (one)]. Successful outcomes were observed in 14 of 29 (48%) subjects with cryptococcal meningitis and five of 10 (50%) subjects with CNS infections due to other fungal pathogens. Posaconazole was well tolerated.

Conclusions: These data suggest that posaconazole, as an oral medication, has clinical activity against fungal infections of the CNS and may provide a valuable alternative to parenteral therapy in patients failing existing antifungal agents.

Keywords: salvage treatment; cryptococcal infections; triazoles; invasive.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. M. Rodriguez, F. J. Pastor, E. Calvo, V. Salas, D. A. Sutton, and J. Guarro
Correlation of In Vitro Activity, Serum Levels, and In Vivo Efficacy of Posaconazole against Rhizopus microsporus in a Murine Disseminated Infection
Antimicrob. Agents Chemother., December 1, 2009; 53(12): 5022 - 5025.
[Abstract] [Full Text] [PDF]

Home page
 In VivoHome page
V. ESPOSITO, R. VIGLIETTI, M. GARGIULO, R. PARRELLA, M. ONOFRIO, V. SANGIOVANNI, D. AMBROSINO, and A. CHIRIANNI
Successful Treatment of Cryptococcal Meningitis with a Combination of Liposomal Amphotericin B, Flucytosine and Posaconazole: Two Case Reports
In Vivo, May 1, 2009; 23(3): 465 - 468.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. I. Morris
Posaconazole: A new oral antifungal agent with an expanded spectrum of activity
Am. J. Health Syst. Pharm., February 1, 2009; 66(3): 225 - 236.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. J. G. T. Ruping, N. Albermann, F. Ebinger, I. Burckhardt, C. Beisel, C. Muller, J. J. Vehreschild, M. Kochanek, G. Fatkenheuer, C. Bangard, et al.
Posaconazole concentrations in the central nervous system
J. Antimicrob. Chemother., December 1, 2008; 62(6): 1468 - 1470.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
E. J Rachwalski, J. T Wieczorkiewicz, and M. H Scheetz
Posaconazole: An Oral Triazole with an Extended Spectrum of Activity
Ann. Pharmacother., October 1, 2008; 42(10): 1429 - 1438.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. A. Stevens, A. Rendon, V. Gaona-Flores, A. Catanzaro, G. M. Anstead, L. Pedicone, and J. R. Graybill
Posaconazole Therapy for Chronic Refractory Coccidioidomycosis
Chest, September 1, 2007; 132(3): 952 - 958.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
O.S. Zmeili and A.O. Soubani
Pulmonary aspergillosis: a clinical update
QJM, June 1, 2007; 100(6): 317 - 334.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
T. D. Ferguson, S. D. Schniederjan, J. Dionne-Odom, M. E. Brandt, M. G. Rinaldi, F. S. Nolte, A. Langston, and S. M. Zimmer
Posaconazole Treatment for Apophysomyces elegans Rhino-Orbital Zygomycosis following Trauma for a Male with Well-Controlled Diabetes
J. Clin. Microbiol., May 1, 2007; 45(5): 1648 - 1651.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
C. A. Kauffman
Histoplasmosis: a Clinical and Laboratory Update
Clin. Microbiol. Rev., January 1, 2007; 20(1): 115 - 132.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
K. P. Liang, I. M. Tleyjeh, W. R. Wilson, G. D. Roberts, and Z. Temesgen
Rhino-Orbitocerebral Mucormycosis Caused by Apophysomyces elegans.
J. Clin. Microbiol., March 1, 2006; 44(3): 892 - 898.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.